van der Aa D, Gisbertz S, Anderegg M, Lagarde S, Klaassen R, Meijer S
J Gastrointest Cancer. 2023; 55(1):270-280.
PMID: 37393217
PMC: 11096198.
DOI: 10.1007/s12029-023-00951-2.
Wang X, Yu N, Cheng G, Zhang T, Wang J, Deng L
Clin Transl Med. 2022; 12(11):e1116.
PMID: 36437506
PMC: 9702363.
DOI: 10.1002/ctm2.1116.
Hosseini K, Ahangari H, Chapeland-Leclerc F, Ruprich-Robert G, Tarhriz V, Dilmaghani A
Adv Pharm Bull. 2022; 12(4):747-756.
PMID: 36415634
PMC: 9675916.
DOI: 10.34172/apb.2022.076.
Kermani A, Ghanbarzadeh R, Joudi Mashhad M, Javadinia S, Emadi Torghabeh A
Front Oncol. 2022; 12:859079.
PMID: 35646696
PMC: 9132043.
DOI: 10.3389/fonc.2022.859079.
Huang J, Zhao L, Gong C, Wang Y, Qu Y, Ji C
Evid Based Complement Alternat Med. 2021; 2021:5386050.
PMID: 34812264
PMC: 8605926.
DOI: 10.1155/2021/5386050.
Omitting surgery in esophageal cancer patients with complete response after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis.
Park J, Yea J, Oh S, Won Park J
Radiat Oncol. 2021; 16(1):219.
PMID: 34775988
PMC: 8591817.
DOI: 10.1186/s13014-021-01947-7.
SUV reduction predicts long-term survival in patients of non-pCR both in the tumor and lymph nodes after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma.
Nagaki Y, Motoyama S, Sato Y, Wakita A, Fujita H, Sasaki Y
World J Surg Oncol. 2021; 19(1):105.
PMID: 33836789
PMC: 8035772.
DOI: 10.1186/s12957-021-02208-3.
Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research.
Ashok A, Tiwari V, Jiwnani S, Karimundackal G, Pramesh C
Ann Gastroenterol Surg. 2019; 3(6):592-597.
PMID: 31788647
PMC: 6875935.
DOI: 10.1002/ags3.12301.
Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy.
Chevrollier G, Giugliano D, Palazzo F, Keith S, Rosato E, Evans Iii N
J Gastrointest Surg. 2019; 24(2):288-298.
PMID: 30809782
DOI: 10.1007/s11605-019-04161-9.
Surveillance or resection after chemoradiation in esophageal cancer.
Park I, Kim J
Ann Transl Med. 2018; 6(4):82.
PMID: 29666805
PMC: 5890038.
DOI: 10.21037/atm.2017.12.16.
Factors associated with the high prevalence of oesophageal cancer in Western Kenya: a review.
Kigen G, Busakhala N, Kamuren Z, Rono H, Kimalat W, Njiru E
Infect Agent Cancer. 2017; 12:59.
PMID: 29142587
PMC: 5670732.
DOI: 10.1186/s13027-017-0169-y.
Neoadjuvant treatment for advanced esophageal cancer: response assessment before surgery and how to predict response to chemoradiation before starting treatment.
Bollschweiler E, Holscher A, Schmidt M, Warnecke-Eberz U
Chin J Cancer Res. 2015; 27(3):221-30.
PMID: 26157318
PMC: 4490195.
DOI: 10.3978/j.issn.1000-9604.2015.04.04.
Exosomal onco-miRs from serum of patients with adenocarcinoma of the esophagus: comparison of miRNA profiles of exosomes and matching tumor.
Warnecke-Eberz U, Chon S, Holscher A, Drebber U, Bollschweiler E
Tumour Biol. 2015; 36(6):4643-53.
PMID: 25631748
DOI: 10.1007/s13277-015-3112-0.
The role of induction therapy.
Moremen J, Skopelja E, Ceppa D
J Thorac Dis. 2014; 6 Suppl 3:S309-13.
PMID: 24876935
PMC: 4037412.
DOI: 10.3978/j.issn.2072-1439.2014.03.10.
Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.
Liu J, Yue J, Xing L, Yu J
Front Med. 2013; 7(2):172-9.
PMID: 23681891
DOI: 10.1007/s11684-013-0268-0.
Response evaluation after neoadjuvant chemoradiation by positron emission tomography-computed tomography for esophageal squamous cell carcinoma.
Park J, Choi J, Moon S, Ahn Y, Lee J, Kim D
Cancer Res Treat. 2013; 45(1):22-30.
PMID: 23613667
PMC: 3629360.
DOI: 10.4143/crt.2013.45.1.22.
A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
Hayashi Y, Xiao L, Suzuki A, Blum M, Sabloff B, Taketa T
Eur J Cancer. 2012; 48(18):3396-404.
PMID: 22853875
PMC: 3869451.
DOI: 10.1016/j.ejca.2012.06.020.
Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R, Warnecke-Eberz U, Alakus H, Kutting F, Brabender J, Vallbohmer D
J Gastrointest Surg. 2011; 16(1):26-34.
PMID: 21956434
DOI: 10.1007/s11605-011-1700-x.
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?.
Monjazeb A, Riedlinger G, Aklilu M, Geisinger K, Mishra G, Isom S
J Clin Oncol. 2010; 28(31):4714-21.
PMID: 20876421
PMC: 3020701.
DOI: 10.1200/JCO.2010.30.7702.